Evidence map›Paper›PMID 29331507›Full record

ArticleMolecular metabolism2018

Adropin: An endocrine link between the biological clock and cholesterol homeostasis.

Sarbani Ghoshal, Joseph R Stevens, Cyrielle Billon, Clemence Girardet, Sadichha Sitaula, Arthur S Leon, D C Rao, James S Skinner, Tuomo Rankinen, Claude Bouchard and 13 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03724825 (Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men), which is not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03724825 completednot on this map

Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men

TypeobservationalSponsorAswan University HospitalRan2018 to 2020Enrolled82ConditionsObesity, DyslipidemiasArmslipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL)), Total testosterone, Adropin, Adiponectin
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Unveiling the multifaceted role of adropin in various diseases (Review).International journal of molecular medicine · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Serum Adropin Levels Are Elevated in Patients With Hyperthyroidism.International journal of endocrinology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 1 country.

Sarbani GhoshalDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Joseph R StevensDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Cyrielle BillonDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Clemence GirardetDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Sadichha SitaulaDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Arthur S LeonSchool of Kinesiology and Leisure Studies, University of Minnesota, Minneapolis, MN, USA.
D C RaoDivision of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.
James S SkinnerDepartment of Kinesiology, Indiana University, Bloomington, IN, USA.
Tuomo RankinenHuman Genomics Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA.
Claude BouchardHuman Genomics Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA.
Marinelle V NuñezDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA; Department of Nutrition, School of Medicine, University of California-Davis, Davis, CA, USA.
Kimber L StanhopeDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA; Department of Nutrition, School of Medicine, University of California-Davis, Davis, CA, USA.
Deborah A HowattSaha Cardiovascular Research Center, Department of Physiology, University of Kentucky, KY, USA.
Alan DaughertySaha Cardiovascular Research Center, Department of Physiology, University of Kentucky, KY, USA.
Jinsong ZhangDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Matthew SchuelkeDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Edward P WeissDepartment of Nutrition and Dietetics, Doisy College of Health Sciences, Saint Louis University, St. Louis, MO, USA.
Alisha R CoffeyCurriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC, USA.
Brian J BennettObesity and Metabolism Unit, Western Human Nutrition Center, USDA-ARS, Davis, CA, USA.
Praveen SethupathyDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Thomas P BurrisDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA.
Peter J HavelDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA; Department of Nutrition, School of Medicine, University of California-Davis, Davis, CA, USA.
Andrew A ButlerDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis University, St. Louis, MO, USA. Electronic address: Andrew.Butler@health.slu.edu.
Saint Louis University · USUniversity of California, Davis · USPennington Biomedical Research Center · USUniversity of Kentucky · USCornell University · USIndiana University Bloomington · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USWashington University in St. Louis · USWestern Human Nutrition Research Center · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4M
UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian Michael Carroll · 1999 to 2026
$31.6M
Development of ROR ligands for treatment of circadian rhythm disordersR01MH092769 · NIMH · ST. LOUIS COLLEGE OF PHARMACY · PI BURRIS, THOMAS P, WALKER, JOHN K. · 2011 to 2020
$6.1M
Mouse Metabolic Phenotyping Center (MMPC) at UC DavisU2CDK092993 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2016 to 2021
$5.9M
Adverse Metabolic Effects of Dietary Sugar _ Ad Libitum vs Energy-Balanced DietsR01HL121324 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAVEL, PETER J, SCHWARZ, JEAN-MARC · 2014 to 2019
$4.2M
REV-ERB ligands for treatment of anxiety disordersR01MH093429 · NIMH · SCRIPPS FLORIDA · PI BURRIS, THOMAS P · 2012 to 2016
$3.6M
Effects of 2wk fructose & HFCS consumption on lipid dysregulation & insulin resisR01HL091333 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAVEL, PETER J · 2008 to 2012
$2.0M
Dietary Fructose: Hormones &TG/Lipoprotein MetabolismR01HL075675 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI HAVEL, PETER J · 2004 to 2008
$1.8M
Fatty acid sources of fructose and HFCS-induced postprandial hypertriglyceridemiaR01HL107256 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAVEL, PETER J, SCHWARZ, JEAN-MARC · 2011 to 2014
$1.5M
Molecular and Biological Functions of miR-29 in Lipid HomeostasisR01DK105965 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SETHUPATHY, PRAVEEN · 2016 to 2019
$1.4M
Systems Genetic Studies of TMAO regulation and AtherosclerosisR01HL128572 · NHLBI · U.S. AGRICULTURAL RESEARCH SERVICE · PI BENNETT, BRIAN JOSEPH · 2015 to 2019
$1.4M
NCATS NIH HHS UL1 TR002345NCRR NIH HHS UL1 RR024992NHLBI NIH HHS R01 HL075675NHLBI NIH HHS R01 HL091333NHLBI NIH HHS R01 HL107256NHLBI NIH HHS R01 HL121324NHLBI NIH HHS R01 HL128572NIDDK NIH HHS K01 DK080886NIDDK NIH HHS P30 DK056350NIDDK NIH HHS R01 DK105965NIDDK NIH HHS U2C DK092993NIMH NIH HHS R01 MH092769NIMH NIH HHS R01 MH093429
6 · The paper itself

Abstract

objectiveIdentify determinants of plasma adropin concentrations, a secreted peptide translated from the Energy Homeostasis Associated (ENHO) gene linked to metabolic control and vascular function.

methodsAssociations between plasma adropin concentrations, demographics (sex, age, BMI) and circulating biomarkers of lipid and glucose metabolism were assessed in plasma obtained after an overnight fast in humans. The regulation of adropin expression was then assessed in silico, in cultured human cells, and in animal models.

resultsIn humans, plasma adropin concentrations are inversely related to atherogenic LDL-cholesterol (LDL-C) levels in men (n = 349), but not in women (n = 401). Analysis of hepatic Enho expression in male mice suggests control by the biological clock. Expression is rhythmic, peaking during maximal food consumption in the dark correlating with transcriptional activation by RORα/γ. The nadir in the light phase coincides with the rest phase and repression by Rev-erb. Plasma adropin concentrations in nonhuman primates (rhesus monkeys) also exhibit peaks coinciding with feeding times (07:00 h, 15:00 h). The ROR inverse agonists SR1001 and the 7-oxygenated sterols 7-β-hydroxysterol and 7-ketocholesterol, or the Rev-erb agonist SR9009, suppress ENHO expression in cultured human HepG2 cells. Consumption of high-cholesterol diets suppress expression of the adropin transcript in mouse liver. However, adropin over expression does not prevent hypercholesterolemia resulting from a high cholesterol diet and/or LDL receptor mutations.

conclusionsIn humans, associations between plasma adropin concentrations and LDL-C suggest a link with hepatic lipid metabolism. Mouse studies suggest that the relationship between adropin and cholesterol metabolism is unidirectional, and predominantly involves suppression of adropin expression by cholesterol and 7-oxygenated sterols. Sensing of fatty acids, cholesterol and oxysterols by the RORα/γ ligand-binding domain suggests a plausible functional link between adropin expression and cellular lipid metabolism. Furthermore, the nuclear receptors RORα/γ and Rev-erb may couple adropin synthesis with circadian rhythms in carbohydrate and lipid metabolism.

Indexed as

Circadian ClocksHomeostasisAdultAgedAnimalsBlood ProteinsCells, CulturedCholesterol, LDLFemaleGlucoseHep G2 CellsHumansIntercellular Signaling Peptides and ProteinsLiverMacaca mulattaMaleBlood ProteinsCholesterol, LDLEnho protein, humanEnho protein, mouseGlucoseIntercellular Signaling Peptides and ProteinsNuclear Receptor Subfamily 1, Group F, Member 1Nuclear Receptor Subfamily 1, Group F, Member 3PeptidesProteinsRORA protein, humanAdropinCardiovascular diseaseCholesterolLDLObesitySex

Identifiers

PMID29331507
PMCPMC5985041
OpenAlexW2776764638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.